TiGenix is developing a drug based on allogeneic expanded adipose-derived stem cells (eASCs) to treat artritis and sepsis. The Phase I trials confirmed the safety and tolerability of the drug. The drug was administered via intravenous injection to patients with sepsis, after it showed a favorable safety and tolerability profile in patients with arthritis. The efficacy in significantly reducing mortality has been demonstrated in several animal models of sepsis through a combination of reduced inflammation, production of anti-microbial effectors, and increased phagocytosis.
Investors reacted, enthusiastically resulting in a profit of 1,67% on the stock market.